Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive symbols : Bysi save search
BeyondSpring Presents Positive Data with Plinabulin for the Prevention of Docetaxel-Induced Neutropenia in Patients with Non-Small Cell Lung Cancer and Breast Cancer at Three Medical Conferences
Published: 2022-12-13 (Crawled : 20:00) - biospace.com/
BYSI | $2.43 12K
|
Health Technology
|
| O: 17.2%
H: 35.14%
C: 15.99%
lung plinabulin breast medical positive cancer
BeyondSpring Pharmaceuticals Announces New Patient-Derived Cancer Model Data for Plinabulin Monotherapy at the AACR-NCI-EORTC Virtual International Conference to Further Support the Positive Clinical Data Already Reported for the Treatment of Small Cell Lung Cancer
Published: 2021-10-20 (Crawled : 14:00) - beyondspringpharma.com
BYSI | $2.43 12K
|
Health Technology
|
| O: 0.96%
H: 6.9%
C: -0.42%
treatment lung cancer positive therapy cancer conference plinabulin
BeyondSpring Pharmaceuticals Announces New Patient-Derived Cancer Model Data for Plinabulin Monotherpy at the AACR-NCI-EORTC Virtual International Conference to Further Support the Positive Clinical Data Already Reported for the Treatment of Small Cell Lung Cancer
Published: 2021-10-20 (Crawled : 12:00) - beyondspringpharma.com
BYSI | $2.43 12K
|
Health Technology
|
| O: 0.96%
H: 6.9%
C: -0.42%
treatment lung cancer positive cancer conference plinabulin
BeyondSpring Pharmaceuticals Announces Positive Final Phase 3 DUBLIN-3 Data with the Plinabulin/Docetaxel Combination
Published: 2021-09-20 (Crawled : 12:00) - biospace.com/
BYSI | $2.43 12K
|
Health Technology
|
| O: -19.1%
H: 7.65%
C: -16.07%
positive phase 3 plinabulin
BeyondSpring Pharmaceuticals Announces Positive Final Phase 3 DUBLIN-3 Data with the Plinabulin/Docetaxel Combination versus Docetaxel Alone in 2nd/3rd Line Non-Small Cell Lung Cancer Patients with EGFR Wild Type at the European Society for Medical Oncology (ESMO) 2021 Congress
Published: 2021-09-20 (Crawled : 12:00) - globenewswire.com
BYSI | $2.43 12K
|
Health Technology
|
| O: -19.1%
H: 7.65%
C: -16.07%
lung cancer europe positive cancer phase 3 plinabulin
BeyondSpring Pharmaceuticals Announces New Positive Data on Plinabulin from Its Chemotherapy-Induced Neutropenia Prevention Program at the European Society for Medical Oncology 2021 Congress
Published: 2021-09-16 (Crawled : 11:00) - beyondspringpharma.com
BYSI | $2.43 12K
|
Health Technology
|
| O: 0.35%
H: 0.95%
C: -2.34%
europe positive therapy plinabulin
BeyondSpring Announces Positive Topline Results from its DUBLIN-3 Registrational Trial of Plinabulin in Combination with Docetaxel for the Treatment of 2nd/3rd Line Non-Small Cell Lung Cancer (NSCLC) with EGFR Wild Type
Published: 2021-08-04 (Crawled : 12:00) - biospace.com/
BYSI | $2.43 12K
|
Health Technology
|
| O: 191.8%
H: 6.76%
C: -5.41%
treatment lung cancer positive results cancer topline trial plinabulin
BeyondSpring Announces Final Positive Data from the PROTECTIVE-1 Phase 3 CIN Program of Plinabulin as a Single Agent Compared to Pegfilgrastim at the American Society of Clinical Oncology (ASCO) Annual Meeting
Published: 2021-06-10 (Crawled : 11:00) - beyondspringpharma.com
BYSI | $2.43 12K
|
Health Technology
|
| O: -0.09%
H: 3.35%
C: 0.26%
positive phase 3 plinabulin
BeyondSpring Announces Three Presentations Highlighting Positive Clinical Outcome Data from the Phase 3 Program of Plinabulin in Combination with Pegfilgrastim for the Prevention of Chemotherapy-Induced Neutropenia at the American Society of Clinical Oncology (ASCO) Annual Meeting
Published: 2021-06-07 (Crawled : 12:00) - globenewswire.com
BYSI | $2.43 12K
|
Health Technology
|
| O: 2.99%
H: 11.25%
C: 9.98%
presentation positive therapy phase 3 plinabulin
BeyondSpring Announces Three Presentations Highlighting Positive Clinical Outcome Data from the Phase 3 Program of Plinabulin in Combination with Pegfilgrastim for the Prevention of Chemotherapy-Induced Neutropenia at the ASCO Annual Meeting
Published: 2021-06-07 (Crawled : 12:00) - biospace.com/
BYSI | $2.43 12K
|
Health Technology
|
| O: 2.99%
H: 11.25%
C: 9.98%
presentation positive therapy phase 3 plinabulin
BeyondSpring Announces New Positive PROTECTIVE-2 Phase 3 Registrational Trial Results at the 2020 San Antonio Breast Cancer Symposium
Published: 2020-12-10 (Crawled : 13:02) - globenewswire.com
BYSI | $2.43 12K
|
Health Technology
|
| O: 0.75%
H: 4.39%
C: 1.31%
breast cancer cancer positive results phase 3 trial trial results symposium
Gainers vs Losers
| 46% | 54% |
Top 10 Gainers
SGBX | $0.26 80.43% 54M
|
Producer Manufacturing
LICN | $1.0 78.57% 3.3M
|
CSSE 4 | $0.2656 74.39% 9.7M
|
Consumer Services
BRFH 4 | $1.89 71.82% 32M
|
Manufacturing
ACON | $0.49 70.14% 24M
|
n/a
BOF | $1.95 66.67% 920K
|
MTC | $3.62 61.61% 790K
|
Technology Services
AMST | $3.22 61.0% 720K
|
Technology Services
PCSA | $2.28 40.74% 37M
|
Producer Manufacturing
EVA | $0.626 39.14% 2.3M
|
Process Industries
Your saved searches
Save your searches and get alerts when important news are released.